摘要
目的探讨类胚胎致死性异常视觉基因1(ELAV1)在卵巢浆液性肿瘤组织中的表达与卵巢浆液性癌化疗耐药及预后的关系。方法采用免疫组化法对2010年1月至2013年2月中国医科大学附属盛京医院收治的40例卵巢浆液性癌(化疗耐药20例和化疗敏感20例)、15例卵巢交界性浆液性瘤、20例卵巢良性浆液性瘤及15例正常卵巢组织中的ELAV1蛋白表达进行检测,并对ELAV1表达与患者临床病理资料及生存率的关系进行分析。结果 (1)ELAV1蛋白胞浆在卵巢浆液性癌中的阳性表达率明显高于卵巢交界性浆液性瘤、卵巢良性浆液性瘤和正常卵巢组织(P<0.05),且在卵巢癌化疗耐药组织中明显高于化疗敏感组织(P<0.05)。(2)ELAV1蛋白胞核阳性表达率在卵巢浆液性癌、卵巢交界性浆液性瘤、卵巢良性浆液性瘤及正常卵巢组织中差异无统计学意义(P>0.05)。(3)胞浆ELAV1的表达与卵巢浆液性癌FIGO病理分期及淋巴结转移情况相关(P<0.05),与患者年龄、是否绝经及分化程度无关(P>0.05)。(4)Kaplan-Meier生存分析提示:ELAV1蛋白胞浆阳性和化疗耐药患者生存时间短。结论 ELAV1可能与卵巢浆液性癌的发生发展相关,可作为预测卵巢浆液性癌化疗耐药及预后的指标。
Objective To study the expression of ELAV1 in ovarian serous tumor and its correlation with chemotherapy resistance and prognosis. Methods Immunohistochemistry was used to test the expressions of ELAV1 in 40 cases of ovarian serous tumor（20 cases of resistance,20 cases of sensitive）,15 cases of borderline tumor,20 ovarian serous benign tumor and 15 normal ovarian tissues.The clinicopathological factors and survival rate of the patients with ovarian serous tumor after operation were analyzed. Results（1） The positive expression rate of cytoplasmic ELAV1 in ovarian serous tumor was higher than that in borderline tumor,ovarian serous benign tumor and normal ovarian tissues（P0.05）.. and the positive expression rate of cytoplasmic ELAV1 in chemotherapy resistance group was significantly higher than that in sensitive group（P0.05）.（2） The positive expression rate of nuclear ELAV1 had no remarkable differences in ovarian serous tumor,borderline tumor,ovarian serous benign tumor and normal ovarian tissues（P0.05）.（3）The expression of cytoplasmic ELAV1 in ovarian serous tumor was closely correlated with FIGO stage and lymphatic metastasis（P0.05）,but not correlated with age,pausimenia or histological grade（P0.05）.（4）Kaplan-Merier survival analysis showed that the patients with cytoplasmic positive ELAV1 and chemotherapy resistance had short survival time. Conclusion ELAV1 are probably involved in early carcinogenesis of ovarian serous tumor.The expression of ELAV1 can be used to predict chemotherapy resistance and prognosis of ovarian serous tumor.
出处
《中国实用妇科与产科杂志》
CAS
CSCD
北大核心
2016年第3期268-272,共5页
Chinese Journal of Practical Gynecology and Obstetrics
